Celltrion has been developing innovative biological treatments and biosimilars since 2002 for the benefit of patients and healthcare professionals. Among its main missions, the company focuses on the care of patients with chronic inflammatory bowel diseases. These often disabling pathologies are constantly increasing among our population, which is why Celltrion Healthcare is working to reduce the burden of its chronic diseases.
Inflammatory bowel diseases, a major health issue
Inflammatory bowel diseases, also known by their acronym IBD, mainly include two pathologies: Crohn’s disease and the ulcerative colitis (UCH).
The incidence of these diseases, which are expressed by outbreaks interspersed with phases of pause or remission, is only increasing. In France, it is estimated that there are around 270,000 people affected by IBD. The number of new cases of Crohn’s disease or UC each year is between 4 and 5 per 100,000 inhabitants.
While these numbers are steadily rising, there is no no cure today. However, if we are not yet able to recover from inflammatory bowel disease, it is still possible to control the disease. Research focuses every day on the mechanisms of these pathologies in order to better understand them and to develop therapies.
Genetics, the role of immunity, the importance of intestinal flora and environmental factors including the role of diet are studied by scientific teams.
Better care for a daily life in revolution
Today, 15% of patients are said to have a severe form of Crohn’s disease or ulcerative colitis and may require hospitalization. Thanks to the improved understanding of the mechanism of IBD, new, more targeted therapies are appearing that have a positive impact the daily life of patients.
Treatments are increasingly administered at home, and the management of these pathologies is becoming multidisciplinary. Taking care of IBD requires a holistic approach, taking into account the medicinal aspect as well as the rules of hygiene and diet, or even the management of the stress of patients who suffer from it.
Celltrion Healthcare, biotherapies at the service of patients
Celltrion Healthcare is a biopharmaceutical company. It was founded in 2002 in South Korea, and the French subsidiary was created in 2019. Specialized in the development of innovative molecules and biosimilar products, it markets treatments used in the management of chronic inflammatory diseases of the intestine.
In order to suggest treatments that best fit into the daily lives of patients, Celltrion Healthcare works with experts, nurses, or patient associations.
Celltrion Healthcare also contributes to the development of IBD care by supporting academic research and training. The company supports learned societies and the community of gastroenterologists by participating in national and international congresses in the field.
Content designed and proposed by L’Agence Delta. The editorial staff of Le Figaro did not participate in the production of this article.